期刊文献+

替吉奥单药三线治疗转移性乳腺癌的临床分析 被引量:1

下载PDF
导出
摘要 目的观察和分析替吉奥单药三线治疗转移性乳腺癌的临床效果。方法从2017年1月~2018年1月期间本院收治的所有转移性乳腺癌患者当中随机选取其中的80例作为本次的观察研究对象,将这80例患者按照数字随机法分为两组各40例的对照组和观察组两组;对照组患者给予常规治疗,观察组患者给予替吉奥三线治疗,对比两组患者的临床疗效和不良反应。结果观察组患者的临床总有效率为25%,对照组患者的临床总有效率为12.5%,差异有统计学意义(P<0.05)。结论采用替吉奥单药三线治疗,能够显著提高转移性乳腺癌患者的临床疗效,减少和降低不良反应的发生。
出处 《实用妇科内分泌电子杂志》 2018年第13期16-17,共2页 Electronic Journal of Practical Gynecological Endocrinology
  • 相关文献

参考文献3

二级参考文献47

  • 1孙燕,石远凯.临床肿瘤内科手册[M].第5版.北京:人民卫生出版社,2013: 134-135.
  • 2Lu HB, Xie XD, Liu ZZ. Research progress in thiple-negative breast cancer [ J ]. Chin German J Clin Oncol, 2010,4 ( 9 ) : 239.
  • 3Shanbhogue AK, Karnad AB, Prasad SR. Tumor response evalua- tion in oncology : current update [ J ]. J Comput Assist Tomogr, 2010,34(4) :479-484.
  • 4Miller AB, Hoogstraten S, Taquet M, et al. Reporting results of eaneer treatment [ J ]. Cancer, 1981,47 ( 1 ) :207.
  • 5Spielmann M, Kalla S, Llombart-Cussae A, et al. Aetivity of gemeitabine in metastatic breast eaneer( MBC )pa-tient previously treated with anthraeyeline--eontaining regimens [ J ]. Eur J cancer, 1997,33 ( suppl 8) : s149.
  • 6Marine F, Aigner J, Lorenzo J, et al. Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase Ⅰ/Ⅱ trialsr [ J ]. Int J Cancer, 2013,133 (4) : 1006-1015.
  • 7Park H, Jung H, Im A, et al. Phase Ⅲ, muhicenter, randoarized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02 [ J]. J Clin 0ncol,2013,31 (14) :1732-1739.
  • 8Stemmler J, di Gioia D, Freier W, et al. Randomised phase II tri- M of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastat- ic breast cancer[J]. Br J Cancer,2011,104(7) :1071-1078.
  • 9Sugimaehi K, Maehara Y, Horikoshi N, et al. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers [ J ]. Oncology, 1999,57(3) :202-210.
  • 10Saek T, Takashima S, Sano M, er al. A phase II study of S-1 in pa- tients with metastatic breast cancer-a Japanese trial by the S-1 Co- operative Study Group, Breast Cancer Working Group[ J]. Breast- Cancer,2004,11 (2) :194-202.

共引文献40

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部